The K+-Dependent and -Independent Pyruvate Kinases Acquire the Active Conformation by Different Mechanisms.

Eukarya pyruvate kinases possess glutamate at position 117 (numbering of rabbit muscle enzyme), whereas bacteria have either glutamate or lysine. Those with E117 are K+-dependent, whereas those with K117 are K+-independent. In a phylogenetic tree, 80% of the sequences with E117 are occupied by T113/K114/T120 and 77% of those with K117 possess L113/Q114/(L,I,V)120. This work aims to understand these residues' contribution to the K+-independent pyruvate kinases using the K+-dependent rabbit muscle enzyme. Residues 117 and 120 are crucial in the differences between the K+-dependent and -independent mutants. K+-independent activity increased with L113 and Q114 to K117, but L120 induced structural differences that inactivated the enzyme. T120 appears to be key in folding the protein and closure of the lid of the active site to acquire its active conformation in the K+-dependent enzymes. E117K mutant was K+-independent and the enzyme acquired the active conformation by a different mechanism. In the K+-independent apoenzyme of Mycobacterium tuberculosis, K72 (K117) flips out of the active site; in the holoenzyme, K72 faces toward the active site bridging the substrates through water molecules. The results provide evidence that two different mechanisms have evolved for the catalysis of this reaction.

Improved yield, stability, and cleavage reaction of a novel tobacco etch virus protease mutant.

The protease catalytic subunit of the nuclear inclusion protein A from tobacco etch virus (TEVp) is widely used to remove tags and fusion proteins from recombinant proteins. Some intrinsic drawbacks to its recombinant production have been studied for many years, such as low solubility, auto-proteolysis, and instability. Some point mutations have been incorporated in the amino acid protease sequence to improve its production. Here, a comprehensive review of each mutation reported so far has been made to incorporate them into a mutant called TEVp7M with a total of seven changes. This mutant with a His7tag at N-terminus was produced with remarkable purification yields (55 mg/L of culture) from the soluble fraction in a single step affinity purification. The stability of His7-TEVp7M was analyzed and compared with the single mutant TEVp S219V, making evident that His7-TEVp7M shows very constant thermal stability against pH variation, whereas TEVp S219V is highly sensitive to this change. The cleavage reaction was optimized by determining the amount of protease that could cleave a 100-fold excess substrate in the shortest possible time at 30 °C. Under these conditions, His7-TEVp7M was able to cleave His-tag in the buffers commonly used for affinity purification. Finally, a structural analysis of the mutations showed that four of them increased the polarity of the residues involved and, consequently, showed increased solubility of TEVp and fewer hydrophobic regions exposed to the solvent. Taken together, the seven changes studied in this work improved stability, solubility, and activity of TEVp producing enough protease to digest large amounts of tags or fusion proteins. KEY POINTS: • Production of excellent yields of a TEVp (TEVp7M) by incorporation of seven changes. • His-tag removal in an excess substrate in the common buffers used for purification. • Incorporated mutations improve polarity, stability, and activity of TEVp7M.

Exploring the differences between the three pyruvate kinase isozymes from Vibrio cholerae in a heterologous expression system.

OBJECTIVE: The genome of Vibrio cholerae has three paralog genes encoding for distinct pyruvate kinases. We were interested in elucidating whether they were expressed, and contributed to the pyruvate kinase activity of V. cholerae. VcIPK and VcIIPK were transformed and expressed in BL21-CodonPlus(DE3)-RIL strain, whereas VcIIIPK could not be transformed. Those studied did contribute to the pyruvate kinase activity of the bacteria. Therefore, our aim was to find an efficient transformation and commonly used over-expression heterologous system for VcIIIPK and develop its purification protocol. RESULTS: vcIpk, vcIIpk and vcIIIpk genes were transformed in six different BL21 expression strains. No transformants were obtained for the vcIIIpk gene using BL21(DE3), BL21(DE3)pLysS and BL21(DE3)CodonPlus-RIL strains. Reduced rates of cell growth were observed for BL21-Gold(DE3)pLysS and Origami B(DE3)pLysS. High efficiency of transformation was obtained for BL21-AI. Using this strain, VcIIIPK was purified but proved to be unstable during its purification and storage. Therefore, the transformation of vcIIIpk gene resulted in a toxic, mildly toxic or nontoxic product for these BL21 strains. Despite VcIIPK and VcIIIPK being phylogenetically related, the preservation of the proteins is drastically different; whereas one is preserved during purification and storage, the other is auto-proteolyzed completely in less than a week.

First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.

The microsporidia are a large group of intracellular parasites with a broad range of hosts, including humans. Encephalitozoon intestinalis is the second microsporidia species most frequently associated with gastrointestinal disease in humans, especially immunocompromised or immunosuppressed individuals, including children and the elderly. The prevalence reported worldwide in these groups ranges from 0 to 60%. Currently, albendazole is most commonly used to treat microsporidiosis caused by Encephalitozoon species. However, the results of treatment are variable, and relapse can occur. Consequently, efforts are being directed toward identifying more effective drugs for treating microsporidiosis, and the study of new molecular targets appears promising. These parasites lack mitochondria, and oxidative phosphorylation therefore does not occur, which suggests the enzymes involved in glycolysis as potential drug targets. Here, we have for the first time characterized the glycolytic enzyme triosephosphate isomerase of E. intestinalis at the functional and structural levels. Our results demonstrate the mechanisms of inactivation of this enzyme by thiol-reactive compounds. The most striking result of this study is the demonstration that established safe drugs such as omeprazole, rabeprazole and sulbutiamine can effectively inactivate this microsporidial enzyme and might be considered as potential drugs for treating this important disease.

[EFFECT OF LOW CARBOHYDRATE DIETS ON WEIGHT LOSS AND GLYCOSILATED HEMOGLOBIN IN PEOPLE WITH TYPE 2 DIABETES: SYSTEMATIC REVIEW]. / EFECTO DE LAS DIETAS BAJAS EN CARBOHIDRATOS SOBRE LA PÉRDIDA DE PESO Y HEMOGLOBINA GLUCOSILADA EN PERSONAS CON DIABETES TIPO 2: REVISIÓN SISTEMÁTICA.

INTRODUCTION: some experts have suggested out that low carbohydrate diets (LCD) are more effective for weight loss and glycemic control. However, long term results are controversial. OBJETIVE: to review and analyze randomized control studies that evaluate the effect of LCD on weight and metabolic control in individuals with type 2 diabetes for a period equal to or greater than 10 months. METHODS: a systematic review was conducted on randomized trials registered in PubMed, EBSCOhost and Scielo to May 15th 2015, published in English and Spanish, with the following search data: "diabetes mellitus" AND "carbohydrate restricted diet" OR "restricted carbohydrate diet" OR "low carbohydrate diet" AND "weight loss". RESULTS: four studies met the inclusion criteria. There were 444 participants between 18-70yo. Follow-up time ranged between 10 to 24 months. Three out of the four studies reported weight reduction with LCD. However, when LCD were compared with other diets no significant differences in weight loss or A1C levels were observed. CONCLUSIONS: this review showed that three of four studies on the LCD were effective for weight loss over a period of 10 to 24 months. However, there was no evidence showing better results than those observed with other diets. Nor, difference in A1C.

Introducción: algunos expertos señalan que las dietas bajas en carbohidratos (DBC) son más efectivas para la reducción de peso y el control glucémico. Sin embargo, los resultados a largo plazo son controversiales. Objetivo: realizar una revisión y análisis de estudios aleatorizados que estudien el efecto de la DBC sobre el control metabólico en individuos con diabetes tipo 2 en un periodo igual o superior a 10 meses. Métodos: se realizó una revisión de estudios aleatorizados controlados publicados en PubMed, EBSCOhost y Scielo hasta el 15 de mayo del 2015. Se buscaron estudios publicados en inglés y español, utilizando los términos de búsqueda: "diabetes mellitus" AND "carbohydrate restricted diet" OR "restricted carbohydrate diet" OR "low carbohydrate diet" AND "weight loss". Resultados: cuatro estudios cumplieron con los criterios de inclusión. El número de participantes fue de 444 individuos, el rango de edad fue de 18 a 70 años. El tiempo de seguimiento osciló entre los 10 y 24 meses. Tres de los cuatro estudios reportaron una reducción de peso con la DBC. Al compararlos con otras dietas no se observaron diferencias significativas en la pérdida de peso ni en los niveles de A1C. Conclusiones: esta revisión muestra que en tres de los cuatro estudios las DBC son efectivas para la pérdida de peso en un período de 10 a 24 meses. Sin embargo, no existen evidencias que demuestren mayor efectividad para la pérdida de peso o la reducción de AIC, cuando se comparan con otras dietas.

Efecto de las dietas bajas en carbohidratos sobre la pérdida de peso y hemoglobina glucosilada en personas con diabetes tipo 2: revisión sistemática / Effect of low carbohydrate diets on weight loss and glycosilated hemoglobin in people with type 2 diabetes: systematic review

Introducción: algunos expertos señalan que las dietas bajas en carbohidratos (DBC) son más efectivas para la reducción de peso y el control glucémico. Sin embargo, los resultados a largo plazo son controversiales. Objetivo: realizar una revisión y análisis de estudios aleatorizados que estudien el efecto de la DBC sobre el control metabólico en individuos con diabetes tipo 2 en un periodo igual o superior a 10 meses. Métodos: se realizó una revisión de estudios aleatorizados controlados publicados en PubMed, EBSCOhost y Scielo hasta el 15 de mayo del 2015. Se buscaron estudios publicados en inglés y español, utilizando los términos de búsqueda: 'diabetes mellitus' AND 'carbohydrate restricted diet' OR 'restricted carbohydrate diet' OR 'low carbohydrate diet' AND 'weight loss'. Resultados: cuatro estudios cumplieron con los criterios de inclusión. El número de participantes fue de 444 individuos, el rango de edad fue de 18 a 70 años. El tiempo de seguimiento osciló entre los 10 y 24 meses. Tres de los cuatro estudios reportaron una reducción de peso con la DBC. Al compararlos con otras dietas no se observaron diferencias significativas en la pérdida de peso ni en los niveles de A1C. Conclusiones: esta revisión muestra que en tres de los cuatro estudios las DBC son efectivas para la pérdida de peso en un período de 10 a 24 meses. Sin embargo, no existen evidencias que demuestren mayor efectividad para la pérdida de peso o la reducción de AIC, cuando se comparan con otras dietas (AU)

Introduction: some experts have suggested out that low carbohydrate diets (LCD) are more effective for weight loss and glycemic control. However, long term results are controversial. Objective: to review and analyze randomized control studies that evaluate the effect of LCD on weight and metabolic control in individuals with type 2 diabetes for a period equal to or greater than 10 months. Methods: a systematic review was conducted on randomized trials registered in PubMed, EBSCOhost and Scielo to May 15th 2015, published in English and Spanish, with the following search data: 'diabetes mellitus' AND 'carbohydrate restricted diet' OR 'restricted carbohydrate diet' OR 'low carbohydrate diet' AND 'weight loss'. Results: four studies met the inclusion criteria. There were 444 participants between 18-70yo. Follow-up time ranged between 10 to 24 months. Three out of the four studies reported weight reduction with LCD. However, when LCD were compared with other diets no significant differences in weight loss or A1C levels were observed. Conclusions: this review showed that three of four studies on the LCD were effective for weight loss over a period of 10 to 24 months. However, there was no evidence showing better results than those observed with other diets. Nor, difference in A1C (AU)

New insights on the mechanism of the K(+-) independent activity of crenarchaeota pyruvate kinases.

Eukarya pyruvate kinases have glutamate at position 117 (numbered according to the rabbit muscle enzyme), whereas in Bacteria have either glutamate or lysine and in Archaea have other residues. Glutamate at this position makes pyruvate kinases K+-dependent, whereas lysine confers K+-independence because the positively charged residue substitutes for the monovalent cation charge. Interestingly, pyruvate kinases from two characterized Crenarchaeota exhibit K+-independent activity, despite having serine at the equivalent position. To better understand pyruvate kinase catalytic activity in the absence of K+ or an internal positive charge, the Thermofilum pendens pyruvate kinase (valine at the equivalent position) was characterized. The enzyme activity was K+-independent. The kinetic mechanism was random order with a rapid equilibrium, which is equal to the mechanism of the rabbit muscle enzyme in the presence of K+ or the mutant E117K in the absence of K+. Thus, the substrate binding order of the T. pendens enzyme was independent despite lacking an internal positive charge. Thermal stability studies of this enzyme showed two calorimetric transitions, one attributable to the A and C domains (Tm of 99.2°C), and the other (Tm of 105.2°C) associated with the B domain. In contrast, the rabbit muscle enzyme exhibits a single calorimetric transition (Tm of 65.2°C). The calorimetric and kinetic data indicate that the B domain of this hyperthermophilic enzyme is more stable than the rest of the protein with a conformation that induces the catalytic readiness of the enzyme. B domain interactions of pyruvate kinases that have been determined in Pyrobaculum aerophilum and modeled in T. pendens were compared with those of the rabbit muscle enzyme. The results show that intra- and interdomain interactions of the Crenarchaeota enzymes may account for their higher B domain stability. Thus the structural arrangement of the T. pendens pyruvate kinase could allow charge-independent catalysis.

Deficiencia de glucosa-6-fosfatodeshidrogenasa: De lo clínico a lo bioquímico / Glucose-6-phosphate dehydrogenase: From the clinical to the biochemical aspects / Deficiência de glicose-6-fosfato desidrogenase: Aspectos clínicos e bioquímicos

La deficiencia de Glucosa-6-fosfato deshidrogenasa (G6PD) es la enzimopatíamás frecuente, con una prevalencia global del 4,9% y con alrededor de 330 a 400 millones de personas afectadas en el mundo. La G6PD desempeña un papel fundamental en el equilibrio redox intracelular, especialmente en los eritrocitos; en condiciones de estrés oxidativo inducido (por ejemplo,por exposición a agentes externos como fármacos, alimentos o infecciones),los hematíes portadores de la variante enzimática y con deficiencia de la actividad enzimática, sufren daños irreversibles que condicionan su destrucción acelerada. La hemólisis explica el espectro de manifestaciones clínicas de esta enfermedad, que incluyen ictericia neonatal, episodios de hemólisis aguda inducida por agentes externos o anemia hemolítica crónica. El presente trabajo hace una reseña de los aspectos epidemiológicos y clínicos de esta enfermedad y revisa los aspectos fisiopatológicos a nivel bioquímico-molecular, con particular énfasis en la caracterización genética,estructural y funcional de las variantes asociadas a la deficiencia de G6PD.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most frequent enzymopathy in humans with a global prevalence of 4.9 % and around 330 to 400 million patients affected worldwide. G6PD plays a fundamental role in the intracellular redox equilibrium, especially in red blood cells (RBC). Under oxidative stress (induced by exposure to external agents like drugs, infections or diet) RBC carrying the deficient variant suffer irreversible damage resulting in their accelerated destruction. This hemolysis explains the clinical manifestations of the disease that include neonatal jaundice, inducedacute hemolysis or chronic hemolytic anemia. This work summarizes the epidemiologic and clinical features of G6PD deficiency, and reviews the molecular pathophysiology of this disease with special emphasis on the genetical, structural and functional characterization of variants causing this pathology.

A deficiência da Glicose-6-FosFato desidrogenase (G6PD) é a enzimopatia mais Frequente, com uma prevalência global do 4,9%, e com aproximadamente 330 a 400 milhões de pessoas afetadas no mundo. A G6PD tem um importante papel no equilíbrio celular redox intracelular, especialmente nos eritrócitos; em condições de estresse oxidativo induzido, (por exemplo, pela exposição a agentes externos como Fármacos, alimentos, ou infecções) as hemácias portadoras da variante enzimática e com defciência da atividade enzimática, sofrem danos irreversíveis que condicionam a sua destruição acelerada. A hemólise explica o espectro de manifestações clínicas desta doença, que incluem icterícia neonatal, episódios de hemólise aguda induzida por agentes externos ou anemia hemolítica crônica. Este trabalho faz uma resenha dos aspectos epidemiológicos e clínicos desta doença, e revisa os aspectos fsiopatológicos no nível bioquímico-molecular, com ênfase especial na caracterização genética, estrutural e funcional das variantes associadas à defciência de G6PD.

Deficiencia de glucosa-6-fosfato deshidrogenasa: De lo clínico a lo bioquímico / Glucose-6-phosphate dehydrogenase: From the clinical to the biochemical aspects / DeficiÛncia de glicose-6-fosfato desidrogenase: Aspectos clínicos e bioquímicos

La deficiencia de Glucosa-6-fosfato deshidrogenasa (G6PD) es la enzimopatía más frecuente, con una prevalencia global del 4,9% y con alrededor de 330 a 400 millones de personas afectadas en el mundo. La G6PD desempeña un papel fundamental en el equilibrio redox intracelular, especialmente en los eritrocitos; en condiciones de estrés oxidativo inducido (por ejemplo, por exposición a agentes externos como fármacos, alimentos o infecciones), los hematíes portadores de la variante enzimática y con deficiencia de la actividad enzimática, sufren daños irreversibles que condicionan su destrucción acelerada. La hemólisis explica el espectro de manifestaciones clínicas de esta enfermedad, que incluyen ictericia neonatal, episodios de hemólisis aguda inducida por agentes externos o anemia hemolítica crónica. El presente trabajo hace una reseña de los aspectos epidemiológicos y clínicos de esta enfermedad y revisa los aspectos fisiopatológicos a nivel bioquímico-molecular, con particular énfasis en la caracterización genética, estructural y funcional de las variantes asociadas a la deficiencia de G6PD.(AU)

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most frequent enzymopathy in humans with a global prevalence of 4.9 % and around 330 to 400 million patients affected worldwide. G6PD plays a fundamental role in the intracellular redox equilibrium, especially in red blood cells (RBC). Under oxidative stress (induced by exposure to external agents like drugs, infections or diet) RBC carrying the deficient variant suffer irreversible damage resulting in their accelerated destruction. This hemolysis explains the clinical manifestations of the disease that include neonatal jaundice, induced acute hemolysis or chronic hemolytic anemia. This work summarizes the epidemiologic and clinical features of G6PD deficiency, and reviews the molecular pathophysiology of this disease with special emphasis on the genetical, structural and functional characterization of variants causing this pathology.(AU)

A deficiÛncia da Glicose-6-fosfato desidrogenase (G6PD) é a enzimopatia mais frequente, com uma prevalÛncia global do 4,9%, e com aproximadamente 330 a 400 milh§es de pessoas afetadas no mundo. A G6PD tem um importante papel no equilíbrio celular redox intracelular, especialmente nos eritrócitos; em condiþ§es de estresse oxidativo induzido, (por exemplo, pela exposiþÒo a agentes externos como fármacos, alimentos, ou infecþ§es) as hemácias portadoras da variante enzimática e com deficiÛncia da atividade enzimática, sofrem danos irreversíveis que condicionam a sua destruiþÒo acelerada. A hemólise explica o espectro de manifestaþ§es clínicas desta doenþa, que incluem icterícia neonatal, episódios de hemólise aguda induzida por agentes externos ou anemia hemolítica cr¶nica. Este trabalho faz uma resenha dos aspectos epidemiológicos e clínicos desta doenþa, e revisa os aspectos fisiopatológicos no nível bioquímico-molecular, com Ûnfase especial na caracterizaþÒo genética, estrutural e funcional das variantes associadas O deficiÛncia de G6PD.(AU)

The stability of G6PD is affected by mutations with different clinical phenotypes.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency worldwide, causing a wide spectrum of conditions with severity classified from the mildest (Class IV) to the most severe (Class I). To correlate mutation sites in the G6PD with the resulting phenotypes, we studied four naturally occurring G6PD variants: Yucatan, Nashville, Valladolid and Mexico City. For this purpose, we developed a successful over-expression method that constitutes an easier and more precise method for obtaining and characterizing these enzymes. The k(cat) (catalytic constant) of all the studied variants was lower than in the wild-type. The structural rigidity might be the cause and the most evident consequence of the mutations is their impact on protein stability and folding, as can be observed from the protein yield, the T50 (temperature where 50% of its original activity is retained) values, and differences on hydrophobic regions. The mutations corresponding to more severe phenotypes are related to the structural NADP+ region. This was clearly observed for the Classes III and II variants, which became more thermostable with increasing NADP+, whereas the Class I variants remained thermolabile. The mutations produce repulsive electric charges that, in the case of the Yucatan variant, promote increased disorder of the C-terminus and consequently affect the binding of NADP+, leading to enzyme instability.

Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia.

Giardiasis is highly prevalent in the developing world, and treatment failures with the standard drugs are common. This work deals with the proposal of omeprazole as a novel antigiardial drug, focusing on a giardial glycolytic enzyme used to follow the cytotoxic effect at the molecular level. We used recombinant technology and enzyme inactivation to demonstrate the capacity of omeprazole to inactivate giardial triosephosphate isomerase, with no adverse effects on its human counterpart. To establish the specific target in the enzyme, we used single mutants of every cysteine residue in triosephosphate isomerase. The effect on cellular triosephosphate isomerase was evaluated by following the remnant enzyme activity on trophozoites treated with omeprazole. The interaction of omeprazole with giardial proteins was analyzed by fluorescence spectroscopy. The susceptibility to omeprazole of drug-susceptible and drug-resistant strains of Giardia lamblia was evaluated to demonstrate its potential as a novel antigiardial drug. Our results demonstrate that omeprazole inhibits giardial triosephosphate isomerase in a species-specific manner through interaction with cysteine at position 222. Omeprazole enters the cytoplasmic compartment of the trophozoites and inhibits cellular triosephosphate isomerase activity in a dose-dependent manner. Such inhibition takes place concomitantly with the cytotoxic effect caused by omeprazole on trophozoites. G. lamblia triosephosphate isomerase (GlTIM) is a cytoplasmic protein which can help analyses of how omeprazole works against the proteins of this parasite and in the effort to understand its mechanism of cytotoxicity. Our results demonstrate the mechanism of giardial triosephosphate isomerase inhibition by omeprazole and show that this drug is effective in vitro against drug-resistant and drug-susceptible strains of G. lamblia.

Structural and functional perturbation of Giardia lamblia triosephosphate isomerase by modification of a non-catalytic, non-conserved region.

BACKGROUND: We have previously proposed triosephosphate isomerase of Giardia lamblia (GlTIM) as a target for rational drug design against giardiasis, one of the most common parasitic infections in humans. Since the enzyme exists in the parasite and the host, selective inhibition is a major challenge because essential regions that could be considered molecular targets are highly conserved. Previous biochemical evidence showed that chemical modification of the non-conserved non-catalytic cysteine 222 (C222) inactivates specifically GlTIM. The inactivation correlates with the physicochemical properties of the modifying agent: addition of a non-polar, small chemical group at C222 reduces the enzyme activity by one half, whereas negatively charged, large chemical groups cause full inactivation. RESULTS: In this work we used mutagenesis to extend our understanding of the functional and structural effects triggered by modification of C222. To this end, six GlTIM C222 mutants with side chains having diverse physicochemical characteristics were characterized. We found that the polarity, charge and volume of the side chain in the mutant amino acid differentially alter the activity, the affinity, the stability and the structure of the enzyme. The data show that mutagenesis of C222 mimics the effects of chemical modification. The crystallographic structure of C222D GlTIM shows the disruptive effects of introducing a negative charge at position 222: the mutation perturbs loop 7, a region of the enzyme whose interactions with the catalytic loop 6 are essential for TIM stability, ligand binding and catalysis. The amino acid sequence of TIM in phylogenetic diverse groups indicates that C222 and its surrounding residues are poorly conserved, supporting the proposal that this region is a good target for specific drug design. CONCLUSIONS: The results demonstrate that it is possible to inhibit species-specifically a ubiquitous, structurally highly conserved enzyme by modification of a non-conserved, non-catalytic residue through long-range perturbation of essential regions.

Determining the molecular mechanism of inactivation by chemical modification of triosephosphate isomerase from the human parasite Giardia lamblia: a study for antiparasitic drug design.

Giardiasis, the most prevalent intestinal parasitosis in humans, is caused by Giardia lamblia. Current drug therapies have adverse effects on the host, and resistant strains against these drugs have been reported, demonstrating an urgent need to design more specific antigiardiasic drugs. ATP production in G. lamblia depends mainly on glycolysis; therefore, all enzymes of this pathway have been proposed as potential drug targets. We previously demonstrated that the glycolytic enzyme triosephosphate isomerase from G. lamblia (GlTIM), could be completely inactivated by low micromolar concentrations of thiol-reactive compounds, whereas, in the same conditions, the activity of human TIM (HuTIM) was almost unaltered. We found that the chemical modification (derivatization) of at least one Cys, of the five Cys residues per monomer in GlTIM, causes this inactivation. In this study, structural and functional studies were performed to describe the molecular mechanism of GlTIM inactivation by thiol-reactive compounds. We found that the Cys222 derivatization is responsible for GlTIM inactivation; this information is relevant because HuTIM has a Cys residue in an equivalent position (Cys217). GlTIM inactivation is associated with a decrease in ligand affinity, which affects the entropic component of ligand binding. In summary, this work describes a mechanism of inactivation that has not been previously reported for TIMs from other parasites and furthermore, we show that the difference in reactivity between the Cys222 in GlTIM and the Cys217 in HuTIM, indicates that the surrounding environment of each Cys residue has unique structural differences that can be exploited to design specific antigiardiasic drugs.

Unraveling the mechanisms of tryptophan fluorescence quenching in the triosephosphate isomerase from Giardia lamblia.

In the native state several proteins exhibit a quenching of fluorescence of their tryptophans. We studied triosephosphate isomerase from Giardia lamblia (GlTIM) to dissect the mechanisms that account for the quenching of fluorescence of its Trp. GlTIM contains four Trp per monomer (Trp75, Trp162, Trp173, and Trp196) distributed throughout the 3D structure. The fluorescence of the denatured enzyme is 3-fold higher than that of native GlTIM. To ascertain the origin of this phenomenon, single and triple mutants of Trp per Phe were made. The intrinsic fluorescence was determined, and the data were interpreted on the basis of the crystal structure of the enzyme. Our data show that the fluorescence of all Trp residues is quenched through two different mechanisms. In one, fluorescence is quenched by aromatic-aromatic interactions due to the proximity and orientation of the indole groups of Trp196 and Trp162. The magnitude of the quenching of fluorescence in Trp162 is higher than in the other three Trp. Fluorescence quenching is also due to energy transfer to the charged residues that surround Trp 75, 173 and 196. Further analysis of the fluorescence of GlTIM showed that, among TIMs from other parasites, Trp at position 12 exhibits rather unique properties.

Key residues of loop 3 in the interaction with the interface residue at position 14 in triosephosphate isomerase from Trypanosoma brucei.

Cysteine 14 is an interface residue that is fundamental for the catalysis and stability of homodimeric triosephosphate isomerase from Trypanosoma brucei (TbTIM). Its side chain is surrounded by a deep pocket of 11 residues that are part of loop 3 of the adjacent monomer. Mutation of this residue to serine (producing single mutant C14S) yields a wild-type-like enzyme that is resistant to the action of sulfhydryl reagents methylmethane thiosulfonate (MMTS) and 5,5-dithiobis(2-nitrobenzoate) (DTNB). This mutant enzyme was a starting point for probing by cysteine scanning the role of four residues of loop 3 in the catalysis and stability of the enzyme. Considering that the conservative substitution of either serine or alanine with cysteine would minimally alter the structure and properties of the environment of the residue in position 14, we made double mutants C14S/A69C, C14S/S71C, C14S/A73C, and C14S/S79C. Three of these double mutants were similar in their kinetic parameters to wild-type TbTIM and the single mutant C14S, but double mutant C14S/A73C showed a greatly reduced k cat. All enzymes had similar CD spectra, but all mutants had thermal stabilities lower than that of wild-type TbTIM. Intrinsic fluorescence was also similar for all enzymes, but the double mutants bound up to 50 times more 1-anilino-8-naphthalene sulfonate (ANS) and were susceptible to digestion with subtilisin. The double mutants were also susceptible to inactivation by sulfhydryl reagents. Double mutant C14S/S79C exhibited the highest sensitivity to MMTS and DTNB, bound a significant amount of ANS, and had the highest sensitivity to subtilisin. Thus, the residues at positions 73 and 79 are critical for the catalysis and stability of TbTIM, respectively.

Species-specific inhibition of Giardia lamblia triosephosphate isomerase by localized perturbation of the homodimer.

Giardia lamblia depends on glycolysis to obtain ATP, highlighting the suitability of glycolytic enzymes as targets for drug design. We studied triosephosphate isomerase from G. lamblia (GlTIM) as a potential species-specific drug target. Cysteine-reactive agents were used as probes, in order to test those regions near to cysteine residues as targets to perturb enzyme structure and activity. Methyl methanethiosulfonate (MMTS) derivatized three of the five Cys per subunit of dimeric GlTIM and induced 50% of inactivation. The 2-carboxyethyl methanethiosulfonate (MTSCE) modified four Cys and induced 97% of inactivation. Inactivation by MMTS or MTSCE did not affect secondary structure, nor induce dimer dissociation; however, Cys modification decreased thermal stability of enzyme. Inactivation and dissociation of the dimer to stable monomers were reached when four Cys were derivatized by 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB). The effects of DTNB were completely abolished when GlTIM was first treated with MMTS. The effect of thiol reagents on human TIM was also assayed; it is 180-fold less sensitive than GlTIM. Collectively, the data illustrate GlTIM as a good target for drug design.

Crosstalk between the subunits of the homodimeric enzyme triosephosphate isomerase.

Homodimeric triosephosphate isomerase (TIM) from Trypanosoma cruzi (TcTIM) and T. brucei (TbTIM) are markedly similar in amino acid sequence and three-dimensional structure. In their dimer interfaces, each monomer has a Cys15 that is surrounded by loop3 of the adjoining subunit. Perturbation of Cys15 by methylmethane thiosulfonate (MMTS) induces abolition of catalysis and structural changes. In the two TIMs, the structural arrangements of their Cys15 are almost identical. Nevertheless, the susceptibility of TcTIM to MMTS is nearly 100-fold higher than in TbTIM. To ascertain the extent to which the characteristics of the interface Cys depend on the dynamics of its own monomer or on those of the adjacent monomer, we studied MMTS action on mutants of TcTIM that had the interface residues of TbTIM, and hybrids that have only one interfacial Cys15 (C15ATcTIM-wild type TbTIM). We found that the solvent exposure of the interfacial Cys depends predominantly on the characteristics of the adjoining monomer. The maximal inhibition of activity induced by perturbation of the sole interface Cys in the C15ATcTIM-TbTIM hybrid is around 60%. Hybrids formed with C15ATcTIM monomers and catalytically inert TbTIM monomers (E168DTbTIM) were also studied. Their activity drops by nearly 50% when the only interfacial Cys is perturbed. These results in conjunction with those on C15ATcTIM-wild type TbTIM hybrid indicate that about half of the activity of each monomer depends on the integrity of each of the two Cys15-loop3 portions of the interface. This could be another reason of why TIM is an obligatory dimer.

Disulfide bridges in the mesophilic triosephosphate isomerase from Giardia lamblia are related to oligomerization and activity.

Triosephosphate isomerase from the mesophile Giardia lamblia (GlTIM) is the only known TIM with natural disulfide bridges. We previously found that oxidized and reduced thiol states of GlTIM are involved in the interconversion between native dimers and higher oligomeric species, and in the regulation of enzymatic activity. Here, we found that trophozoites and cysts have different oligomeric species of GlTIM and complexes of GlTIM with other proteins. Our data indicate that the internal milieu of G. lamblia is favorable for the formation of disulfide bonds. Enzyme mutants of the three most solvent exposed Cys of GlTIM (C202A, C222A, and C228A) were prepared to ascertain their contribution to oligomerization and activity. The data show that the establishment of a disulfide bridge between two C202 of two dimeric GlTIMs accounts for multimerization. In addition, we found that the establishment of an intramonomeric disulfide bond between C222 and C228 abolishes catalysis. Multimerization and inactivation are both reversed by reducing conditions. The 3D structure of the C202A GlTIM was solved at 2.1 A resolution, showing that the environment of the C202 is prone to hydrophobic interactions. Molecular dynamics of an in silico model of GlTIM when the intramonomeric disulfide bond is formed, showed that S216 is displaced 4.6 A from its original position, causing loss of hydrogen bonds with residues of the active-site loop. This suggests that this change perturb the conformational state that aligns the catalytic center with the substrate, inducing enzyme inactivation.

An unusual triosephosphate isomerase from the early divergent eukaryote Giardia lamblia.

Recombinant triosephosphate isomerase from the parasite Giardia lamblia (GlTIM) was characterized and immunolocalized. The enzyme is distributed uniformly throughout the cytoplasm. Size exclusion chromatography of the purified enzyme showed two peaks with molecular weights of 108 and 55 kDa. Under reducing conditions, only the 55-kDa protein was detected. In denaturing gel electrophoresis without dithiothreitol, the enzyme showed two bands with molecular weights of 28 and 50 kDa; with dithiotretitol, only the 28-kDa protein was observed. These data indicate that GlTIM may exist as a tetramer or a dimer and that, in the former, the two dimers are covalently linked by disulfide bonds. The kinetics of the dimer were similar to those of other TIMs. The tetramer exhibited half of the kcat of the dimer without changes in the Km. Studies on the thermal stability and the apparent association constants between monomers showed that the tetramer was slightly more stable than the dimer. This finding suggests the oligomerization is not related to enzyme thermostability as in Thermotoga maritima. Instead, it could be that oligomerization is related to the regulation of catalytic activity in different states of the life cycle of this mesophilic parasite.